Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Genexol-PM + carboplatin
- Development stage
- Unknown
- Lead developer
- Samyang Group
- Modality
- Nanoparticles → Drug Delivery Systems, Small Molecules
- Administration
- Intravenous
01
Overview
Genexol-PM + carboplatin is a combination chemotherapy regimen primarily investigated as a first-line treatment for advanced ovarian cancer. Genexol-PM is a Cremophor EL-free, biodegradable polymeric micelle formulation of paclitaxel developed by Samyang Corporation. By utilizing a polymeric micelle delivery system, it avoids the hypersensitivity reactions and toxicities associated with conventional paclitaxel formulations that use Cremophor EL as a solvent. Carboplatin is a platinum-based antineoplastic agent that interferes with DNA repair mechanisms. Together, the combination works synergistically: paclitaxel stabilizes microtubules to inhibit mitosis, while carboplatin induces DNA cross-linking to prevent replication and transcription, leading to apoptosis in tumor cells. Clinical trials led by Asan Medical Center have evaluated this combination's efficacy and safety, demonstrating non-inferiority to standard paclitaxel regimens in epithelial ovarian cancer.
- Brand names
- Genexol-PM
- Other names
- paclitaxel-loaded polymeric micelle + carboplatin
02
Targets
TUBB (Tubulin (alpha and beta subunits))DNA
Beyond the preview
Go deeper on Genexol-PM + carboplatin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Genexol-PM + carboplatin.